Subscribe
shutterstock_706912843_adragan
adragan / Shutterstock.com
4 March 2019Big Pharma

CMA accuses hydrocortisone suppliers of anti-competitive behaviour

The UK Competition and Markets Authority (CMA) has provisionally found that pharmaceutical companies  Auden Mckenzie and  Waymade engaged in anti-competitive behaviour relating to hydrocortisone tablets.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
NHS to receive £8m from Aspen over anti-competitive practices
15 August 2019   Drugmaker Aspen has offered to pay the UK’s National Health System £8 million to resolve competition concerns.
Big Pharma
Phenytoin judgment will help clarify unfair pricing tests, says UK’s CMA
12 March 2020   The UK Competition and Markets Authority has welcomed a Court of Appeal ruling allowing it to press ahead with cases against Pfizer and Flynn Pharma over the unfair pricing of an epilepsy treatment.
Europe
CMA fines drugmakers £260m for 10,000% price hike
15 July 2021   The UK’s Competition and Markets Authority has imposed fines of £260 million on drug companies for raising the price of life-saving hydrocortisone tablets by 10,000%.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
NHS to receive £8m from Aspen over anti-competitive practices
15 August 2019   Drugmaker Aspen has offered to pay the UK’s National Health System £8 million to resolve competition concerns.
Big Pharma
Phenytoin judgment will help clarify unfair pricing tests, says UK’s CMA
12 March 2020   The UK Competition and Markets Authority has welcomed a Court of Appeal ruling allowing it to press ahead with cases against Pfizer and Flynn Pharma over the unfair pricing of an epilepsy treatment.
Europe
CMA fines drugmakers £260m for 10,000% price hike
15 July 2021   The UK’s Competition and Markets Authority has imposed fines of £260 million on drug companies for raising the price of life-saving hydrocortisone tablets by 10,000%.

More on this story

Big Pharma
NHS to receive £8m from Aspen over anti-competitive practices
15 August 2019   Drugmaker Aspen has offered to pay the UK’s National Health System £8 million to resolve competition concerns.
Big Pharma
Phenytoin judgment will help clarify unfair pricing tests, says UK’s CMA
12 March 2020   The UK Competition and Markets Authority has welcomed a Court of Appeal ruling allowing it to press ahead with cases against Pfizer and Flynn Pharma over the unfair pricing of an epilepsy treatment.
Europe
CMA fines drugmakers £260m for 10,000% price hike
15 July 2021   The UK’s Competition and Markets Authority has imposed fines of £260 million on drug companies for raising the price of life-saving hydrocortisone tablets by 10,000%.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent